TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26033499
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy (LRT) combined with arsenic trioxide (As2 O3)
Study: 21570485
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) control
Study: 18308112
Drug: Neoadjuvant chemohormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemohormonal therapy (complete androgen blockage, docetaxel 70 mg/m2 on day 2, estramustine 280 mg three times daily on days 1 to 5 every 21 days) before radical prostatectomy.
Study: 16799983
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 10 mg once daily
Study: 12542507
Drug: IFNbeta‐1a 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 30 mcg intramuscularly once weekly for 2 years
Study: 9298051
Drug: 0.5% topical
Normalized name: Carac 0.5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% topical ketorolac
Study: 22506537
Drug: Betahistine 12
Normalized name: betahistine 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 12 mg
Study: 11673338
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF, Molgramostim) 40 microg intracoronary injection followed by 10 microg/kg subcutaneous for 2 weeks
Study: 6101550
Drug: Behaviour Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour Therapy Programme (BTP)
Study: 6101550
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Methadone Withdrawal Programme and Behaviour Therapy Programme (MBT)
Study: 29021336
Drug: RAASi (renin-angiotensin-aldosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAASi (renin-angiotensin-aldosterone system inhibitors)
Study: 26843962
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy group (ITG) with target HbA1c <6.2%, BP <120/75 mm Hg, LDL <80 mg/dL
Study: 26843962
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy group (CTG) with target HbA1c <6.9%, BP <130/80 mm Hg, LDL <120 mg/dL
Study: 24704117
Drug: Contigen (collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contigen (collagen gel)
Study: 9741406
Drug: Neuromuscular blocking
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blocking agents (NMBA) and steroids
Study: 3050336
Drug: Topical fusidic
Normalized name: fusidate Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fusidic acid 2% cream
Study: 3050336
Drug: Oral dicloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dicloxacillin 500 mg twice a day
Study: 22925176
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous sulphate 200 mg tablets, 60 mg elemental iron, three times a day for 4 weeks)
Study: 22925176
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (200 mg in divided doses on alternate days by slow intravenous infusion)
Study: 2645796
Drug: Doxepin hydrochloride
Normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin hydrochloride 150 mg (N = 9)
Study: 31746819
Drug: Balloon Eustachian
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon Eustachian Tuboplasty with concurrent tympanocentesis
Study: 30427274
Drug: Plavix (18.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plavix (18.75 mg PO q24h for 7 days)
Study: 30427274
Drug: Generic clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic clopidogrel (18.75 mg PO q24h for 7 days)
Study: 28571258
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of implant within two days of insertion
Study: 28571258
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of implant after three months of insertion
Study: 21145244
Drug: Phrenic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phrenic nerve infiltration (PNI) with 10 ml of 2% lidocaine
Study: 21145244
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block (SNB) with 10 ml of 0.5% plain bupivacaine
Study: 17955789
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone once daily
Study: 11286448
Drug: Metronidazole 400mg
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 400mg orally eight hourly for 5 days postoperatively
Study: 9305320
Drug: Tolcapone 100
Normalized name: tolcapone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone 100 mg three times daily
Study: 9305320
Drug: Tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone 200 mg three times daily
Study: 3732372
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of hydrochlorothiazide 25 mg and triamterene 50 mg
Study: 3732372
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of furosemide 40 mg and triamterene 50 mg
Study: 24760962
Drug: Ischemic postconditioning
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ischemic postconditioning (IPost) administered by 4 cycles of 1-minute reocclusion and 1-minute reperfusion, starting 1 minute after opening, followed by stenting.
Study: 22301933
Drug: Higher-protein HMF
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-protein HMF (1.4 g protein/100 mL)
Study: 22301933
Drug: Standard-protein HMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-protein HMF (1.0 g protein/100 mL)
Study: 20842617
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence during the maintenance phase
Study: 16170294
Drug: Serum progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Serum progesterone (P) levels on the day of human chorionic gonadotropin (hCG) administration
Study: 10490789
Drug: (‐)‐HCA (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: (‐)‐HCA (3.0 g/d)
Study: 8526959
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia with sufentanil (15 micrograms initial bolus)
Study: 1638578
Drug: Gentamicin-Clindamycin (G/C)
Normalized name: clindamycin Topical Solution [C/T/S]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-Clindamycin (G/C)
Study: 6707245
Drug: Thioridazine plus
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine plus either social skills training or holistic health therapy
Study: 30853647
Drug: Purgative Manna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purgative Manna drops (5 drops/kg divided into three doses per day for three days)
Study: 29903598
Drug: Cognitive functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive functional therapy
Study: 29903598
Drug: Combined manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined manual therapy and motor control exercises
Study: 26628861
Drug: Gratisovir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gratisovir (400 mg daily)
Study: 26628861
Drug: Grateziano (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grateziano (400 mg daily)
Study: 24627237
Drug: Docetaxel 45
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 45 mg/m² with bolus and 44 h infusion of 5-Fu/Lv (arm T)
Study: 24627237
Drug: Irinotecan 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/m² with bolus and 44 h infusion of 5-Fu/Lv (arm C)
Study: 24627237
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in advanced GC
Study: 6192505
Drug: Tendamistate 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tendamistate 100 mg
Study: 6192505
Drug: Tendamistate 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tendamistate 200 mg
Study: 31649125
Drug: Intravenous microtracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous microtracer of 10 µg [14C]nemiralisib
Study: 31649125
Drug: Inhaled nonradiolabeled
Normalized name: Radiolabelled DUNP19
DrugBank: RAD 502 (DB17328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nonradiolabeled 1000 µg dose
Study: 31649125
Drug: Oral 800
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral 800 µg dose of [14C]nemiralisib
Study: 25395210
Drug: NSC 631570
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSC 631570 administered i.v. in a single therapeutic dose
Study: 25395210
Drug: NSC 631570
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSC 631570 administered i.v. in an outpatient setting
Study: 25395210
Drug: NSC 631570
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSC 631570 administered in an inpatient setting
Study: 25395210
Drug: Active participants
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active participants after drug injection
Study: 24421054
Drug: β‐glucan 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐glucan 10 mg capsules administered twice a day for 10 days
Study: 19144772
Drug: CRA13 1-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRA13 1-80 mg
Study: 19144772
Drug: CRA13 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRA13 40 mg with food
Study: 19144772
Drug: CRA13 40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRA13 40-80 mg
Study: 12642692
Drug: Thalidomide monotherapy
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide monotherapy (200 to 1,200 mg/day)
Study: 9457020
Drug: Headgear (combination)
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headgear (combination)
Study: 15879435
Drug: Budesonide (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (inhaled corticosteroid)
Study: 10172461
Drug: Budesonide (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (once-daily administration in dry powder form via Turbuhaler)
Study: 1761121
Drug: Heparin (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (low-dose continuous administration)
Study: 10365742
Drug: No Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Heparin
Study: 6813959
Drug: Trimipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (25 mg, two tablets)
Study: 30756339
Drug: Iloprost inhalation
Normalized name: Iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost inhalation (20 µg)
Study: 22166801
Drug: Total iron
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total iron (diet and supplements)
Study: 22166801
Drug: Iron from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron from supplements
Study: 17721018
Drug: hANP administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hANP administration
Study: 15206993
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice 200 ml
Study: 12375798
Drug: Topoisomerase I
Normalized name: Topoisomerase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topoisomerase I inhibitors in nonplatinum combinations
Study: 9661000
Drug: Pefloxacin 800
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 800 mg
Study: 8619366
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 0.05 IU/kg/day
Study: 8619366
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 0.10 IU/kg/day
Study: 8619366
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 0.20 IU/kg/day
Study: 344042
Drug: Bromocryptine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocryptine (average daily dose 71 mg)
Study: 26387012
Drug: Hypothermia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia treatment for neonatal encephalopathy
Study: 9142061
Drug: Monovalent live
Normalized name: INFLUENZA A (H1N1) MONOVALENT LIVE VACCINE,NASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent live attenuated (RA27/3 strain) rubella vaccine
Study: 24256334
Drug: Lemon candy
Normalized name: LEMON
DrugBank: Lemon (DB10538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemon candy (standard treatment)
Study: 23919857
Drug: E2V/DNG (oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2V/DNG (oestradiol valerate/dienogest) administered in a dynamic dosing regimen (26/2 regimen)
Study: 16263828
Drug: 0.24 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24 mg/kg x wk GH
Study: 16263828
Drug: 0.37 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.37 mg/kg x wk GH
Study: 12748212
Drug: Pharmacist led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist led intervention to improve drug compliance
Study: 12748212
Drug: Model with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model with addition of beta blockers
Study: 8820427
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg) + Quinidine (100 mg daily)
Study: 3893701
Drug: Ibuprofen-codeine phosphate
Normalized name: codeine / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-codeine phosphate combination
Study: 27559840
Drug: Adapted-dose (AD)
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted-dose (AD) group: increase of ribavirin dose if D0AUC0‐4h <1755 mcg·h·L
Study: 27559840
Drug: Fixed-dose (FD)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose (FD) group: standard of care with peginterferon‐α2a 180 mcg·wk and weight‐based ribavirin 1000‐1200 mg/d during 48 weeks
Study: 27559840
Drug: Adapted-dose (AD)
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted-dose (AD) group
Study: 27559840
Drug: Fixed-dose (FD)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose (FD) group
Study: 22909077
Drug: Antibiotic/steroid-coated sutures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic/steroid-coated sutures (200 cases)
Study: 22909077
Drug: Antiseptic-soaked and
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseptic-soaked and antibiotic/steroid-coated sutures (141 cases)
Study: 9914571
Drug: Danazol 200
Normalized name: danazol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 200 mg daily during the luteal phase
Study: 2102130
Drug: Ketanserin (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40-80 mg/day, oral therapy)
Study: 2102130
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg, sublingual; 10 mg, intravenous)
Study: 30579447
Drug: Low-fidelity simulation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fidelity simulation training with tablet-paired physical endovascular tool navigation (group S)
Study: 30579447
Drug: Low-fidelity simulation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fidelity simulation training with tablet-paired touch-gesture navigation (group A)
Study: 21733417
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg orally twice per day for 10 days
Study: 21733417
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg orally three times per day for 10 days
Study: 7982769
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (levels 9.5 +/- 1 mg/l)
Study: 31990581
Drug: Collagen peptide
Normalized name: Procollagen peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen peptide (CP) supplementation (10 g/day for 12 weeks)
Study: 28123764
Drug: Anthracycline chemotherapy
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline chemotherapy
Study: 16777690
Drug: Irinotecan (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (130 mg/m2 IV over 90 minutes) and Docetaxel (50 mg/m2 IV over 60 minutes) on Day 1 q3 weeks for 6 cycles
Study: 15577128
Drug: Raloxifene at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene at a dosage of 60 or 120 mg/day for 3 years
Study: 10989959
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg 17beta-estradiol valerate (E2)
Study: 31421989
Drug: HDM SLIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM SLIT tablets for 4 weeks followed by dual therapy with JCP SLIT tablets for 8 weeks
Study: 31421989
Drug: JCP SLIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: JCP SLIT tablets for 4 weeks followed by dual therapy with HDM SLIT tablets for 8 weeks
Study: 31421989
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with both SLIT tablets administered within 5 min after 4 weeks of monotherapy
Study: 28330808
Drug: Sunitinib (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (continuous daily dosing schedule)
Study: 23357837
Drug: 100-mg pregabalin
Normalized name: pregabalin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg pregabalin capsule
Study: 23357837
Drug: 100-mg pregabalin
Normalized name: pregabalin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg pregabalin solution (capsule dissolved in water)
Study: 21192149
Drug: Rimonabant (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (20 mg/d)
Study: 18629368
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination strategy (perindopril/indapamide 2 mg/0.625 mg, with possible increase to 3 mg/0.935 mg, and 4 mg/1.250 mg if needed)
Study: 18629368
Drug: Sequential monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential monotherapy approach (atenolol 50 mg, followed by losartan 50 mg and amlodipine 5 mg if needed)
Study: 18629368
Drug: Stepped-care strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care strategy (valsartan 40 mg, followed by valsartan 80 mg and valsartan 80 mg + hydrochlorothiazide 12.5 mg if needed)
Study: 16613215
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (including probucol and pravastatin)
Study: 12621389
Drug: Telithromycin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (800 mg daily, repeated doses)
Study: 12621389
Drug: Telithromycin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (800 mg, single dose)
Study: 12621389
Drug: Telithromycin (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (1600 mg, single dose)
Study: 12621389
Drug: Telithromycin (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (2400 mg, single dose)
Study: 6890700
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from placebo to active medication
Study: 30764769
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for 7 days
Study: 30764769
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for 14 days
Study: 26983390
Drug: UC-MSC treatment
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSC treatment (0.5-1.0×10(6) cells/kg/month for 3 months)
Study: 26983390
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment only (control group)
Study: 23277248
Drug: Methylphenidate (30
Normalized name: methylphenidate (30/70 release) 10 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (30 mg)
Study: 11008278
Drug: Balneophysical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneophysical treatments (process expectation)
Study: 28285432
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (BC) 3.2 g/day
Study: 28285432
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (WP) 3.2 g/day
Study: 19065892
Drug: PTS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTS plus Aspirin
Study: 19065892
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group D (no aspirin)
Study: 12477757
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg twice daily + Amoxicillin 1 g twice daily
Study: 8829556
Drug: Indomethacin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.4 mg/kg bolus followed by continuous infusion 0.4 mg/kg/h
Study: 8829556
Drug: Indomethacin 0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.1, 0.2, and 0.3 mg/kg bolus followed by continuous infusion of 0.1, 0.2, and 0.3 mg/kg/h
Study: 9229881
Drug: Rectal application
Normalized name: Rectal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal application of 100 mg indomethacin
Study: 29053981
Drug: Dim Red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim Red Light Therapy (dRLT)